Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics Extends Herbicide Deal with Bayer CropScience

NEW YORK, Nov. 17 (GenomeWeb News) - Paradigm Genetics said today that it has signed a two-year extension of its herbicide discovery collaboration with Bayer CropScience.

 

This extension, which will take the partnership through Sept. 2006, is the second since the companies began the arrangement, and will include research fees and success fees for assay deliveries. Paradigm also stands to receive royalties from Bayer under the terms of the original deal.

 

Additional terms were not disclosed.

 

According to Paradigm, it began in 1998 working to discover novel herbicides that are to be developed and marketed by Bayer CropScience. The term of the inital deal was three years, and included the option for a two-year extension.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.